The Bio Report
Using AI to Generate Mini-Protein Therapeutics
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:27:43
- Mais informações
Informações:
Sinopse
Mini-proteins have the power and performance of an antibody with the ability to bind tightly to a target. But because of their small size, it can penetrate into places where small molecules can go. Ordaōs Bio is leveraging its generative AI platform to develop a pipeline of mini-protein therapeutics. We spoke to David Longo, co-founder and CEO of Ordaōs, about the company’s focus on mini-proteins, its generative AI platform, and why its building its own pipeline around rare disease indications and partnering with other drug developers on other indications.